Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter

Use tags to find relevant records

3D printed implants

Ablation methods

Allogeneic mesenchymal stem cells

Ambulatory ECG monitoring

Aortic abdominal aneurysm

Aortic root replacement

Arthroplasty

Arthroscopy

Assisted ventilation

Atherectomy

Austria

Autologous chondrocyte implantation

Automated external defibrillator

AV fistula

AV graft

Balloon kyphoplasty

Bariatric surgery

Baroreflex activation therapy

Barrett’s oesophagus

Belgium

Benign prostatic hyperplasia

Biopsy

Bone Conductive Hearing Device

Breast reconstruction

Bronchial thermoplasty

Burns

Caesarean section

Cancer

Capsule endoscopy

Carbon ion therapy

Cardiac ablation

Cardiac computer tomography

Cardiac pacemaker

Cardiac resynchronization therapy

Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Cardiovascular devices

Cardiovascular procedures

Carotid endarterectomy

Cataract

Cell therapy

Cholecystectomy

Chronic obstructive pulmonary disease

Chronic wounds

Clinical guidelines

Cochlear implants

Commissioning

Companion diagnostic tests

Computed tomography

Conditional reimbursement

Connected medical devices

Continuous glucose monitoring (CGM)

Coronary interventions

Coronary percutaneous revascularization procedures

Coronary procedures

Coronavirus

Coverage with evidence development (CED)

Radiofrequency ablation of bone

23

Jul 2024

Percutaneous CT-guided ablation of tumors will be reimbursed via Convention from November 2024 in Belgium

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

28

Jul 2017

Radiofrequency ablation is recommended for inclusion into benefit catalogue with restrictions for patients with metastatic spinal lesions in Austria

The Ludwig Boltzmann Institute – Health Technology Assessment (LBI-HTA) has published results of systematic literature review of evidence in relation to efficacy and safety of radiofrequency ablation for patients with metastatic spinal lesions. In conclusion, LBI-HTA recommended radiofrequency ablation of spinal metastatic lesions for inclusion in benefit catalogue with restrictions.